Navigation Links
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Date:11/19/2008

(IBS) currently enrolling in a 480 patient Phase 2b trial.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering.

SafeHarbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
2. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
6. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
7. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
10. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  In today,s ever-changing marketplace, call centers ... mobile, increasingly connected, and increasingly impatient with slow service. ... interaction channels and tools is driving call centers to ... According to research by benchmarking firm, Best ... segment in a call center study realize the impact ...
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... RnRMarketResearch.com adds Syringes and ... that provides an overview of syringes and needles ... in-house databases, secondary and primary research. ... pipeline spread across 124 pages, talking about 13 ... 5 figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... July 28, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... developer, manufacturer and marketer of orthopedic implants in China, today ... financial results on August 16, 2011, before the market opens. ... a.m. ET on August 16, 2011 to discuss second quarter ...
... Soligenix, Inc. (Soligenix or the Company) (OTC BB: ... amendment of its North American licensing partnership with Sigma ... development and commercialization of orBec® (oral beclomethasone dipropionate or ... part of the amended agreement, Sigma - Tau has ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 2Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 3Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 4Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 5Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 6Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 7Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe 8
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Health notes that while an overwhelming number of Hispanics believe people can ... The overwhelming 70 percent of participants queried said making diet changes was important. ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... bodybuilding and fitness site and the largest online retailer of nutritional supplements, ... BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... Beach, CA (PRWEB) , ... August 03, 2015 ... ... individuals suffering from ALS and amputation , AUGUST 3, 2015 – Since winning ... category in March 2015, Not Impossible – an organization whose mission is to ...
(Date:8/3/2015)... NC (PRWEB) , ... August 03, 2015 , ... The ... by experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was ... Zereshki has decided to share her cookbook Recipes from My Persian Kitchen with the ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... AxoGen, ... nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August ... A live webcast and subsequent archived replay of the Company’s presentation may be accessed ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... 20 CHF,International has been selected as the ... Fund) new Principal Recipient (PR) for,HIV/AIDS prevention, treatment ... awarded an HIV proposal in Round 3 programming., ... years, CHF will be directly responsible for,managing Honduras, ...
... How familiar are you,with the health of your family ... festivity of the Thanksgiving holiday, taking a good look ... That,s why Acting Surgeon General Steven K. Galson, ... Family History Day.,He encourages everyone to use the occasion ...
... System Sets ... Space-Saving Standard, WARRENDALE, ... EP Mobile MR Injection System today, MEDRAD once again,addresses the ... with market-leading injector technology suited for,small spaces. (Logo: ...
... ... ... Subspecialty,Radiology (F&S) has added 31 subspecialty radiologists to support the,growing ... industry,s largest subspecialty teleradiology network. F&S,radiologists are musculoskeletal, body, cardiac, ...
... day the Los,Angeles Times reported that cancer survivors could ... care proposals, smooth,talking Mitt Romney is slated to discuss ... report, cancer survivors "could not be,sure of getting coverage ... government or job-related plan and had to seek insurance ...
... Irvine, Calif., Nov. 20 2007 Vase or face" When presented ... a vase or the faces of two people, what we observe ... brains. , In this example, whether you see faces ... since the image always stays exactly the same, said John Serences, ...
Cached Medicine News:Health News:CHF International Named Global Fund Principal Recipient in Honduras 2Health News:Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 2Health News:Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 3Health News:MEDRAD Mobile MR Injector Meets Challenges of MR Trailers 2Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 2Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 3Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 4Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 5Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 7Health News:Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 8Health News:Mitt's Millions Can't Buy Iowans Health Care Reform 2Health News:Scientists uncover how the brain controls what the eyes see 2
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Short, narrow paddle angled 45 degree inserts through the side port stab incision and is ideal for effective manipulation of the lens during anterior chamber phacoemulsification....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Medicine Products: